Biocon
-
{
- All
- News
- Videos
-
Stock In Focus: Biocon Share Price Rises 3% After This Block Deal; Details Inside
- Wednesday September 9, 2026
- Author: NDTV Profit Desk
Revenue from operations increased 10% YoY to Rs 4,336 crore in Q1FY27 from Rs 3,942 crore in the year-ago quarter.
-
www.ndtvprofit.com
-
Biocon Q1 Results: Profit Spikes 350%, Revenue Exceeds Rs 4,300 Crore
- Wednesday August 5, 2026
- Author: Nikhil Tiwari
Biocon Q1 profit surged 348% to Rs. 141 crore as revenue rose 10% to Rs. 4,336 crore. Biosimilars and generics led growth, while EBITDA margin remained stable.
-
www.ndtvprofit.com
-
Who Is Claire Mazumdar? The Likely New Face Of Biocon To Lead In Post-Kiran Era
- Tuesday May 5, 2026
- Author: NDTV Profit News, Edited by: Hemarghya Bal
Kiran Mazumdar-Shaw stated that Claire might potentially seek assistance from other Mazumdar family members.
-
www.ndtvprofit.com
-
Who Is Claire Mazumdar? Meet Kiran Mazumdar-Shaw's Chosen Successor At Biocon
- Tuesday May 5, 2026
- Feature | Edited by Ritu Singh
Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.
-
www.ndtv.com
-
'No Plans To Hang Up My Boots Yet': Kiran Mazumdar-Shaw Clears Air On Niece's Succession At Biocon
- Tuesday May 5, 2026
- Author: NDTV Profit News, Edited by: Hemarghya Bal
In an X post, Shaw confirmed that she has named Claire Mazumdar as the future leader of the company, but it will happen at the right time.
-
www.ndtvprofit.com
-
Biocon CEO Says Their Next Growth Trigger Could Arrive In Just 30 Days In The US Market
- Friday February 27, 2026
- Author: Yukta Baid
Mittal said the opportunity remains meaningful despite the broader GLP-1 market shifting toward newer therapies such as Ozempic and Mounjaro.
-
www.ndtvprofit.com
-
Biocon Opens Rs 4,500-Crore QIP To Fund Biologics Integration
- Monday January 12, 2026
- Author: Shubhayan Bhattacharya
Of the total proceeds via the share sale, up to Rs 3,620 crore will be utilised mainly towards payment to Mylan Inc. (Viatris).
-
www.ndtvprofit.com
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
- Monday January 5, 2026
- Author: Motilal Oswal Financial Services
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
www.ndtvprofit.com
-
Biocon Employee, 26, Found Dead At Bengaluru Office
- Tuesday December 30, 2025
- India News | Reported by Deepak Bopanna, Edited by Akash Majumder
A 26-year-old employee of Biocon was found dead on the company premises at Bengaluru's Electronic City Phase-II on Tuesday.
-
www.ndtv.com
-
Biocon-Biologics Deal To Unlock Shareholder Value, Hulio Under Full Control: Kiran Mazumdar Shaw
- Wednesday December 24, 2025
- Author: Nikita Prasad
Upon securing the global manufacturing and commercial rights for Hulio, Shaw said that Hulio is an asset where Biocon has a transfer pricing and profit sharing arrangement.
-
www.ndtvprofit.com
-
'Buy' Biocon Shares Maintains Motilal Oswal Despite EPS Dilution; Sees Upto 20% Upside
- Tuesday December 9, 2025
- Author: Motilal Oswal Financial Services
Biocon’s bets big on biologics; integration to unlock shareholder value, says Motilal Oswal.
-
www.ndtvprofit.com
-
Biocon Unveils Rs 11,450 Crore Capital Plan For Biologics Integration
- Saturday December 6, 2025
- Author: Ann Jacob
The preferential issue will involve 17.12 crore equity shares of Biocon at a price determined under SEBI norms, aggregating up to Rs 6,950 crore.
-
www.ndtvprofit.com
-
Biocon Eyes Acceleration Phase As USFDA Draft Guidelines Open Door To Cheaper Biosimilars: Kiran Mazumdar-Shaw
- Friday November 21, 2025
- Author: Divya Prata
Shaw said Biocon’s growth trajectory over the next five years will be “very exciting,” with even larger opportunities emerging beyond 2030 as big-ticket biologics go off patent.
-
www.ndtvprofit.com
-
US Proposal Could Halve Biocon's Biosimilar Development Costs
- Friday November 14, 2025
- World News | Reuters
India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.
-
www.ndtv.com
-
Stock In Focus: Biocon Share Price Rises 3% After This Block Deal; Details Inside
- Wednesday September 9, 2026
- Author: NDTV Profit Desk
Revenue from operations increased 10% YoY to Rs 4,336 crore in Q1FY27 from Rs 3,942 crore in the year-ago quarter.
-
www.ndtvprofit.com
-
Biocon Q1 Results: Profit Spikes 350%, Revenue Exceeds Rs 4,300 Crore
- Wednesday August 5, 2026
- Author: Nikhil Tiwari
Biocon Q1 profit surged 348% to Rs. 141 crore as revenue rose 10% to Rs. 4,336 crore. Biosimilars and generics led growth, while EBITDA margin remained stable.
-
www.ndtvprofit.com
-
Who Is Claire Mazumdar? The Likely New Face Of Biocon To Lead In Post-Kiran Era
- Tuesday May 5, 2026
- Author: NDTV Profit News, Edited by: Hemarghya Bal
Kiran Mazumdar-Shaw stated that Claire might potentially seek assistance from other Mazumdar family members.
-
www.ndtvprofit.com
-
Who Is Claire Mazumdar? Meet Kiran Mazumdar-Shaw's Chosen Successor At Biocon
- Tuesday May 5, 2026
- Feature | Edited by Ritu Singh
Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.
-
www.ndtv.com
-
'No Plans To Hang Up My Boots Yet': Kiran Mazumdar-Shaw Clears Air On Niece's Succession At Biocon
- Tuesday May 5, 2026
- Author: NDTV Profit News, Edited by: Hemarghya Bal
In an X post, Shaw confirmed that she has named Claire Mazumdar as the future leader of the company, but it will happen at the right time.
-
www.ndtvprofit.com
-
Biocon CEO Says Their Next Growth Trigger Could Arrive In Just 30 Days In The US Market
- Friday February 27, 2026
- Author: Yukta Baid
Mittal said the opportunity remains meaningful despite the broader GLP-1 market shifting toward newer therapies such as Ozempic and Mounjaro.
-
www.ndtvprofit.com
-
Biocon Opens Rs 4,500-Crore QIP To Fund Biologics Integration
- Monday January 12, 2026
- Author: Shubhayan Bhattacharya
Of the total proceeds via the share sale, up to Rs 3,620 crore will be utilised mainly towards payment to Mylan Inc. (Viatris).
-
www.ndtvprofit.com
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
- Monday January 5, 2026
- Author: Motilal Oswal Financial Services
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
www.ndtvprofit.com
-
Biocon Employee, 26, Found Dead At Bengaluru Office
- Tuesday December 30, 2025
- India News | Reported by Deepak Bopanna, Edited by Akash Majumder
A 26-year-old employee of Biocon was found dead on the company premises at Bengaluru's Electronic City Phase-II on Tuesday.
-
www.ndtv.com
-
Biocon-Biologics Deal To Unlock Shareholder Value, Hulio Under Full Control: Kiran Mazumdar Shaw
- Wednesday December 24, 2025
- Author: Nikita Prasad
Upon securing the global manufacturing and commercial rights for Hulio, Shaw said that Hulio is an asset where Biocon has a transfer pricing and profit sharing arrangement.
-
www.ndtvprofit.com
-
'Buy' Biocon Shares Maintains Motilal Oswal Despite EPS Dilution; Sees Upto 20% Upside
- Tuesday December 9, 2025
- Author: Motilal Oswal Financial Services
Biocon’s bets big on biologics; integration to unlock shareholder value, says Motilal Oswal.
-
www.ndtvprofit.com
-
Biocon Unveils Rs 11,450 Crore Capital Plan For Biologics Integration
- Saturday December 6, 2025
- Author: Ann Jacob
The preferential issue will involve 17.12 crore equity shares of Biocon at a price determined under SEBI norms, aggregating up to Rs 6,950 crore.
-
www.ndtvprofit.com
-
Biocon Eyes Acceleration Phase As USFDA Draft Guidelines Open Door To Cheaper Biosimilars: Kiran Mazumdar-Shaw
- Friday November 21, 2025
- Author: Divya Prata
Shaw said Biocon’s growth trajectory over the next five years will be “very exciting,” with even larger opportunities emerging beyond 2030 as big-ticket biologics go off patent.
-
www.ndtvprofit.com
-
US Proposal Could Halve Biocon's Biosimilar Development Costs
- Friday November 14, 2025
- World News | Reuters
India's Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.
-
www.ndtv.com